Lucius version of Dacomitinib is now available

Release date: 2026-07-21 17:40:58     Recommended: 206

Lucius version of Dacomitinib is now available

Cutaneous adverse reactions and management strategies for Dacomitinib

Rash and exfoliative skin reactions are highly characteristic adverse effects of dacomitinib, with incidence and severity closely related to sunlight exposure, requiring proactive prevention and management.

(1) Overall rash incidence is 78%, with 21% being grade 3 or 4; exfoliative skin reactions (any grade) occur in 7%, with severe (grade 3/4) at 1.8%.

(2) Management principle: persistent grade 2 or any grade 3/4 skin reaction requires dose interruption; after recovery to ≤ grade 1, resume at the same dose or reduced dose depending on severity.

(3) Preventive measures include starting moisturizers and strict sun protection at treatment initiation; once grade 1 rash appears, topical antibiotics and corticosteroids may be added; for grade 2 or above, initiate oral antibiotics (e.g., doxycycline or minocycline).

Other common adverse reactions, serious events, and drug interactions for Dacomitinib

Beyond ILD and skin reactions, this agent affects multiple systems and has clear CYP2D6-mediated drug interactions.

(1) Most common (>20%) adverse reactions in descending order: diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), weight loss (26%), alopecia (23%), cough (21%), and pruritus (21%).

(2) Serious adverse reactions (≥1%) are mainly diarrhea (2.2%) and ILD (1.3%), requiring close monitoring.

(3) Drug interactions: avoid concomitant use with proton pump inhibitors (PPIs) as they significantly reduce dacomitinib concentrations; topical antacids or H2-receptor antagonists may be used as alternatives, but dosing times must be staggered (at least 6 hours before and 10 hours after H2-antagonist administration). Additionally, co-administration with CYP2D6 substrates may increase the toxicity of the latter, especially when a minor concentration increase of the substrate poses serious risk; concomitant use should be avoided.

Special population precautions for Dacomitinib

For different physiological and pathological states, this agent has clear recommendations or restrictions, particularly in reproductive, elderly, and hepatic/renal impairment populations requiring special caution.

(1) Embryo-fetal toxicity: animal studies suggest potential fetal harm; therefore, women of childbearing potential must use effective contraception during treatment and for at least 17 days after the last dose; pregnancy requires risk-benefit assessment and disclosure of risks.

(2) Lactation: because it may be excreted into breast milk and cause serious adverse reactions, breastfeeding should be suspended during treatment and for at least 17 days after the last dose.

(3) Elderly patients (≥65 years): exploratory analyses show higher incidence of grade 3/4 adverse reactions and more frequent dose interruptions or discontinuations due to AEs, requiring enhanced monitoring.

(4) Renal impairment: no dose adjustment needed for mild or moderate impairment; severe impairment.